Associations between CYP19A1 polymorphisms, Native American ancestry, and breast cancer risk and mortality: the Breast Cancer Health Disparities Study

Stephanie D. Boone, Kathy B. Baumgartner, Richard N. Baumgartner, Avonne Connor, Christina M. Pinkston, Shesh N. Rai, Elizabeth C. Riley, Lisa M. Hines, Anna R. Giuliano, Esther M. John, Mariana C. Stern, Gabriela Torres-Mejía, Roger K. Wolff, Martha L. Slattery

Research output: Contribution to journalArticle

Abstract

The cytochrome p450 family 19 gene (CYP19A1) encodes for aromatase, which catalyzes the final step in estrogen biosynthesis and conversion of androgens to estrogens. Genetic variation in CYP19A1 is linked to higher circulating estrogen levels and increased aromatase expression. Using data from the Breast Cancer Health Disparities Study, a consortium of three population-based case–control studies in the United States (n = 3,030 non-Hispanic Whites; n = 2,893 Hispanic/Native Americans (H/NA) and Mexico (n = 1,810), we examined influence of 25 CYP19A1 tagging single-nucleotide polymorphisms (SNPs) on breast cancer risk and mortality, considering NA ancestry. Odds ratios (ORs) and 95 % confidence intervals (CIs) and hazard ratios estimated breast cancer risk and mortality. After multiple comparison adjustment, none of the SNPs were significantly associated with breast cancer risk or mortality. Two SNPs remained significantly associated with increased breast cancer risk in women of moderate to high NA ancestry (≥29 %): rs700518, ORGG1.36, 95 % CI 1.11–1.67 and rs11856927, ORGG1.35, 95 % CI 1.05–1.72. A significant interaction was observed for rs2470144 and menopausal status (padj = 0.03); risk was increased in postmenopausal (ORAA1.22, 95 % CI 1.05–1.14), but not premenopausal (ORAA0.78, 95 % CI 0.64–0.95) women. The absence of an overall association with CYP19A1 and breast cancer risk is similar to previous literature. However, this analysis provides support that variation in CYP19A1 may influence breast cancer risk differently in women with moderate to high NA ancestry. Additional research is warranted to investigate the how variation in an estrogen-regulating gene contributes to racial/ethnic disparities in breast cancer.

Original languageEnglish (US)
Pages (from-to)1461-1471
Number of pages11
JournalCancer Causes and Control
Volume25
Issue number11
DOIs
StatePublished - Oct 31 2014
Externally publishedYes

Fingerprint

North American Indians
Breast Neoplasms
Mortality
Health
Confidence Intervals
Estrogens
Single Nucleotide Polymorphism
Aromatase
Mexico
Hispanic Americans
Androgens
Genes
Odds Ratio
Research

Keywords

  • Breast cancer mortality
  • Breast cancer risk
  • CYP19A1 polymorphisms
  • Native American ancestry

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Associations between CYP19A1 polymorphisms, Native American ancestry, and breast cancer risk and mortality : the Breast Cancer Health Disparities Study. / Boone, Stephanie D.; Baumgartner, Kathy B.; Baumgartner, Richard N.; Connor, Avonne; Pinkston, Christina M.; Rai, Shesh N.; Riley, Elizabeth C.; Hines, Lisa M.; Giuliano, Anna R.; John, Esther M.; Stern, Mariana C.; Torres-Mejía, Gabriela; Wolff, Roger K.; Slattery, Martha L.

In: Cancer Causes and Control, Vol. 25, No. 11, 31.10.2014, p. 1461-1471.

Research output: Contribution to journalArticle

Boone, SD, Baumgartner, KB, Baumgartner, RN, Connor, A, Pinkston, CM, Rai, SN, Riley, EC, Hines, LM, Giuliano, AR, John, EM, Stern, MC, Torres-Mejía, G, Wolff, RK & Slattery, ML 2014, 'Associations between CYP19A1 polymorphisms, Native American ancestry, and breast cancer risk and mortality: the Breast Cancer Health Disparities Study', Cancer Causes and Control, vol. 25, no. 11, pp. 1461-1471. https://doi.org/10.1007/s10552-014-0448-5
Boone, Stephanie D. ; Baumgartner, Kathy B. ; Baumgartner, Richard N. ; Connor, Avonne ; Pinkston, Christina M. ; Rai, Shesh N. ; Riley, Elizabeth C. ; Hines, Lisa M. ; Giuliano, Anna R. ; John, Esther M. ; Stern, Mariana C. ; Torres-Mejía, Gabriela ; Wolff, Roger K. ; Slattery, Martha L. / Associations between CYP19A1 polymorphisms, Native American ancestry, and breast cancer risk and mortality : the Breast Cancer Health Disparities Study. In: Cancer Causes and Control. 2014 ; Vol. 25, No. 11. pp. 1461-1471.
@article{e904d542a44240b9851fe6a1785111b0,
title = "Associations between CYP19A1 polymorphisms, Native American ancestry, and breast cancer risk and mortality: the Breast Cancer Health Disparities Study",
abstract = "The cytochrome p450 family 19 gene (CYP19A1) encodes for aromatase, which catalyzes the final step in estrogen biosynthesis and conversion of androgens to estrogens. Genetic variation in CYP19A1 is linked to higher circulating estrogen levels and increased aromatase expression. Using data from the Breast Cancer Health Disparities Study, a consortium of three population-based case–control studies in the United States (n = 3,030 non-Hispanic Whites; n = 2,893 Hispanic/Native Americans (H/NA) and Mexico (n = 1,810), we examined influence of 25 CYP19A1 tagging single-nucleotide polymorphisms (SNPs) on breast cancer risk and mortality, considering NA ancestry. Odds ratios (ORs) and 95 {\%} confidence intervals (CIs) and hazard ratios estimated breast cancer risk and mortality. After multiple comparison adjustment, none of the SNPs were significantly associated with breast cancer risk or mortality. Two SNPs remained significantly associated with increased breast cancer risk in women of moderate to high NA ancestry (≥29 {\%}): rs700518, ORGG1.36, 95 {\%} CI 1.11–1.67 and rs11856927, ORGG1.35, 95 {\%} CI 1.05–1.72. A significant interaction was observed for rs2470144 and menopausal status (padj = 0.03); risk was increased in postmenopausal (ORAA1.22, 95 {\%} CI 1.05–1.14), but not premenopausal (ORAA0.78, 95 {\%} CI 0.64–0.95) women. The absence of an overall association with CYP19A1 and breast cancer risk is similar to previous literature. However, this analysis provides support that variation in CYP19A1 may influence breast cancer risk differently in women with moderate to high NA ancestry. Additional research is warranted to investigate the how variation in an estrogen-regulating gene contributes to racial/ethnic disparities in breast cancer.",
keywords = "Breast cancer mortality, Breast cancer risk, CYP19A1 polymorphisms, Native American ancestry",
author = "Boone, {Stephanie D.} and Baumgartner, {Kathy B.} and Baumgartner, {Richard N.} and Avonne Connor and Pinkston, {Christina M.} and Rai, {Shesh N.} and Riley, {Elizabeth C.} and Hines, {Lisa M.} and Giuliano, {Anna R.} and John, {Esther M.} and Stern, {Mariana C.} and Gabriela Torres-Mej{\'i}a and Wolff, {Roger K.} and Slattery, {Martha L.}",
year = "2014",
month = "10",
day = "31",
doi = "10.1007/s10552-014-0448-5",
language = "English (US)",
volume = "25",
pages = "1461--1471",
journal = "Cancer Causes and Control",
issn = "0957-5243",
publisher = "Springer Netherlands",
number = "11",

}

TY - JOUR

T1 - Associations between CYP19A1 polymorphisms, Native American ancestry, and breast cancer risk and mortality

T2 - the Breast Cancer Health Disparities Study

AU - Boone, Stephanie D.

AU - Baumgartner, Kathy B.

AU - Baumgartner, Richard N.

AU - Connor, Avonne

AU - Pinkston, Christina M.

AU - Rai, Shesh N.

AU - Riley, Elizabeth C.

AU - Hines, Lisa M.

AU - Giuliano, Anna R.

AU - John, Esther M.

AU - Stern, Mariana C.

AU - Torres-Mejía, Gabriela

AU - Wolff, Roger K.

AU - Slattery, Martha L.

PY - 2014/10/31

Y1 - 2014/10/31

N2 - The cytochrome p450 family 19 gene (CYP19A1) encodes for aromatase, which catalyzes the final step in estrogen biosynthesis and conversion of androgens to estrogens. Genetic variation in CYP19A1 is linked to higher circulating estrogen levels and increased aromatase expression. Using data from the Breast Cancer Health Disparities Study, a consortium of three population-based case–control studies in the United States (n = 3,030 non-Hispanic Whites; n = 2,893 Hispanic/Native Americans (H/NA) and Mexico (n = 1,810), we examined influence of 25 CYP19A1 tagging single-nucleotide polymorphisms (SNPs) on breast cancer risk and mortality, considering NA ancestry. Odds ratios (ORs) and 95 % confidence intervals (CIs) and hazard ratios estimated breast cancer risk and mortality. After multiple comparison adjustment, none of the SNPs were significantly associated with breast cancer risk or mortality. Two SNPs remained significantly associated with increased breast cancer risk in women of moderate to high NA ancestry (≥29 %): rs700518, ORGG1.36, 95 % CI 1.11–1.67 and rs11856927, ORGG1.35, 95 % CI 1.05–1.72. A significant interaction was observed for rs2470144 and menopausal status (padj = 0.03); risk was increased in postmenopausal (ORAA1.22, 95 % CI 1.05–1.14), but not premenopausal (ORAA0.78, 95 % CI 0.64–0.95) women. The absence of an overall association with CYP19A1 and breast cancer risk is similar to previous literature. However, this analysis provides support that variation in CYP19A1 may influence breast cancer risk differently in women with moderate to high NA ancestry. Additional research is warranted to investigate the how variation in an estrogen-regulating gene contributes to racial/ethnic disparities in breast cancer.

AB - The cytochrome p450 family 19 gene (CYP19A1) encodes for aromatase, which catalyzes the final step in estrogen biosynthesis and conversion of androgens to estrogens. Genetic variation in CYP19A1 is linked to higher circulating estrogen levels and increased aromatase expression. Using data from the Breast Cancer Health Disparities Study, a consortium of three population-based case–control studies in the United States (n = 3,030 non-Hispanic Whites; n = 2,893 Hispanic/Native Americans (H/NA) and Mexico (n = 1,810), we examined influence of 25 CYP19A1 tagging single-nucleotide polymorphisms (SNPs) on breast cancer risk and mortality, considering NA ancestry. Odds ratios (ORs) and 95 % confidence intervals (CIs) and hazard ratios estimated breast cancer risk and mortality. After multiple comparison adjustment, none of the SNPs were significantly associated with breast cancer risk or mortality. Two SNPs remained significantly associated with increased breast cancer risk in women of moderate to high NA ancestry (≥29 %): rs700518, ORGG1.36, 95 % CI 1.11–1.67 and rs11856927, ORGG1.35, 95 % CI 1.05–1.72. A significant interaction was observed for rs2470144 and menopausal status (padj = 0.03); risk was increased in postmenopausal (ORAA1.22, 95 % CI 1.05–1.14), but not premenopausal (ORAA0.78, 95 % CI 0.64–0.95) women. The absence of an overall association with CYP19A1 and breast cancer risk is similar to previous literature. However, this analysis provides support that variation in CYP19A1 may influence breast cancer risk differently in women with moderate to high NA ancestry. Additional research is warranted to investigate the how variation in an estrogen-regulating gene contributes to racial/ethnic disparities in breast cancer.

KW - Breast cancer mortality

KW - Breast cancer risk

KW - CYP19A1 polymorphisms

KW - Native American ancestry

UR - http://www.scopus.com/inward/record.url?scp=84911959909&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84911959909&partnerID=8YFLogxK

U2 - 10.1007/s10552-014-0448-5

DO - 10.1007/s10552-014-0448-5

M3 - Article

C2 - 25088806

AN - SCOPUS:84911959909

VL - 25

SP - 1461

EP - 1471

JO - Cancer Causes and Control

JF - Cancer Causes and Control

SN - 0957-5243

IS - 11

ER -